« Return to News | Miscellaneous

Clinquest Group Acquires Stake in Enceladus Pharmaceuticals

Monday, July 9, 2007 02:31 PM

Amsterdam-based CRO Clinquest Group has acquired a stake in Enceladus Pharmaceuticals, the Netherlands-based developer of the inflammatory disorder treatment Nanocort—the product is in phase II trials. Clinquest also gathered a group of additional investment groups to back Enceladus as it brings more products to market.

“The participation of Clinquest in our activities allows us to complete the phase IIa clinical proof-of-concept trial with Nanocort that is currently ongoing in The Netherlands. Therefore this means a major boost to our clinical development track,” said Bart Metselaar, founder and chief executive officer of Enceladus.

Clinquest said it believed in Enceladus’ development pipeline and in the future of Nanocort.

“By entering in this risk-sharing arrangement, we are able to support the further development of Nanocort and the entire liposomal development platform most efficiently,” said Cees Wortel, chief executive officer of Clinquest Group.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.